‘Patchy’ UK AHSNs To Be Addressed Ahead Of 2023 Relicensing
A new remit for the NHS’ innovation vehicles, hopes for Integrated Care Systems and a new diagnostics trends report from Deloitte were on the agenda at a UK life sciences sector policy conference.
You may also be interested in...
MHRA Must Seize UK Digital And Diagnostics Opportunity: ABHI Perspectives On Enabling Regulation – Part 2
IVD and healthtech industry representatives give their views on how the future UK medtech system can be shaped to be agile and responsive to patients’ needs, mindful that the regulator must deliver a standalone regulatory system and functional UKCA marking in less than two years.
As the UK NHS Medtech Funding Mandate finally becomes live, the medtech industry is pressing the case for another mechanism that will allow more innovation onto the UK market.
Often seen as complicated to access, beset with high entry barriers and with no guarantee of product adoption, the UK NHS is at once a lucrative and tricky market to succeed in for medtech innovators. A new MedTech Landscape Review, from the AHSN Network, has taken on the tasks of signposting and explaining the system, its adoption pathways and its various tools and programs, in an effort to point the way for manufacturers who want to access the NHS.